Related Experiment Video

Updated: May 10, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Fusions between dendritic cells and whole tumor cells as anticancer vaccines

Shigeo Koido1, Sadamu Homma, Masato Okamoto

  • 1Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan ; Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan ; Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan.

Oncoimmunology
|June 14, 2013
PubMed

Insights

Cancer vaccines using dendritic cell (DC)-cancer cell fusions show promise by presenting diverse tumor antigens. While effective in animal models, clinical trials require optimization for robust antitumor effects.

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Dendritic cells (DCs) are crucial for initiating immune responses against cancer.
  • Various strategies exist to deliver tumor-associated antigens (TAAs) to DCs for enhanced cancer immunotherapy.
  • DC-cancer cell fusions offer a method to present a wide range of TAAs, including novel ones.

Purpose of the Study:

  • To review recent advancements in anticancer vaccines utilizing DC-cancer cell fusions.
  • To highlight the potential and challenges of this approach in cancer treatment.

Main Methods:

  • Fusion of dendritic cells (DCs) with whole cancer cells.
  • Processing and presentation of tumor-associated antigens (TAAs) by fused cells.
  • Analysis of immune responses in preclinical and clinical settings.

Main Results:

  • DC-cancer cell fusions process a broad spectrum of TAAs, including unknown molecules.
  • These fusions present TAAs with MHC Class I and II molecules and co-stimulatory signals.
  • Potent antitumor immune responses are observed in animal models, but clinical efficacy needs improvement.

Conclusions:

  • DC-cancer cell fusions represent a promising strategy for developing novel anticancer vaccines.
  • Further research and optimization are needed to translate preclinical success into robust clinical antitumor effects.
Keywords:
anticancer vaccinescell fusionsdendritic cells

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Vaccinations01:51

Vaccinations

Overview
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.